IXJ - ASCO Annual Meeting 2024: Breakthrough Treatments Hint At Renewed Hope For Patients And Investors
2024-07-17 04:42:00 ET
Summary
- As medical companies leverage the power of artificial intelligence, genomics, and other groundbreaking discoveries, the boundaries between technology and healthcare continue to blur, presenting potential opportunities for both patients and investors.
- CAR-T therapies are moving beyond the blood cancer niche and are showing promise in fighting solid tumors, potentially expanding their use to a much broader patient population.
- Antibody drug conjugates could also have tremendous growth potential, given the benefits they appear to offer over traditional chemotherapy.
Originally published on July 16, 2024
In June, the American Society of Clinical Oncology (ASCO) hosted its 60th Annual Meeting, drawing over 40,000 attendees from around the globe. The conference is the premier oncology event of the year, showcasing clinical readouts on the most promising innovations in cancer diagnosis and treatment. ...
ASCO Annual Meeting 2024: Breakthrough Treatments Hint At Renewed Hope For Patients And Investors